Introduction
Pfizer declared $9.3 billion of dividends to its shareholders in 2023, $1.65 per share. Its net income that year was $2.1 billion. A dividend more than four times the year's profit did not create a loss, did not appear among Pfizer's expenses and did not change its earnings per share. It reduced retained earnings, created a liability until it was paid, and then reduced cash. That is the whole of a dividend's journey through the statements, and the reason it never touches the income statement is the same reason the trace is so short: a dividend is a distribution to owners, not a cost of running the business.
Declaration and Payment: Two Steps
A cash dividend has two accounting moments. On the declaration date, when the board approves the dividend, the company becomes legally obliged to pay it, so it records the dividend at that point: retained earnings fall and a dividends payable liability appears. On the payment date, cash leaves and the liability is settled. The record date in between, which decides who receives the dividend, has no accounting effect.
Suppose a company declares a $100 dividend in December and pays $75 of it before year end, with the rest paid in January:
The income statement does not change. Retained earnings fall by the full $100 declared, cash falls by the $75 paid, and the unpaid $25 sits in dividends payable. In January, cash and the liability both fall by $25. Under US GAAP, dividends paid are always a financing cash flow.
Pfizer's 2023 annual report shows the same split: $9,316 million declared against retained earnings, $9,247 million paid in financing activities, and dividends payable rising by the $69 million difference, to $2,372 million, because each quarter's dividend is declared before it is paid. How the declared amount moves retained earnings from one balance sheet to the next is covered in the retained earnings roll-forward.
What Bankers Check
Because a dividend is not an expense, the income statement says nothing about whether a company can afford it. The tests come from the other two statements. The payout ratio, dividends divided by net income, shows how much of earnings is distributed, but a better test compares dividends with free cash flow (operating cash flow minus capital expenditures), since dividends are paid in cash. Pfizer's 2023 dividend far exceeded its net income, which was depressed by inventory write-offs and a $3.5 billion non-cash revenue reversal for Paxlovid, its COVID-19 treatment, and was supported by cash generation and by borrowing; a company that funds dividends with debt year after year is eventually forced to choose between leverage and its payout. How dividends sit alongside borrowing and buybacks in the financing section is explained in cash flow from financing activities.
- Payout ratio
Dividends declared as a percentage of net income, showing how much of a year's earnings a company distributes to shareholders. A ratio above 100% means dividends exceed earnings and must be funded from accumulated cash, other cash flows or borrowing.
A ratio based on free cash flow is usually more informative, because one-off non-cash charges can push the earnings-based ratio far above 100% in a year when cash generation easily covered the dividend. Pfizer's 2023 fails the cash test too: $8.7 billion of operating cash flow less $3.9 billion of capital expenditures left about $4.8 billion of free cash flow, roughly half the $9.2 billion it paid out.
Two variants trace slightly differently. A stock dividend distributes shares instead of cash, moving an amount from retained earnings to paid-in capital with no cash flow and no change in total equity. And dividends paid to minority shareholders of a subsidiary reduce noncontrolling interests rather than the parent's retained earnings, while still appearing in financing activities. In every case, the rule holds: dividends move equity and cash, never net income, and the comparison with buybacks is developed in issuing stock and buying it back.
